117 related articles for article (PubMed ID: 2977219)
1. Rapid rise of serum testosterone following discontinuation of long term treatment of prostate carcinoma with an LHRH-agonist.
Kreis W; Budman DR; Delli Bovi P; Vinciguerra V
Onkologie; 1988 Dec; 11(6):292-3. PubMed ID: 2977219
[No Abstract] [Full Text] [Related]
2. Treatment of advanced carcinoma of the prostate by LHRH-agonists.
Claes HI; Vandenbussche L; Vereecken RL
Prog Clin Biol Res; 1987; 243A():229-37. PubMed ID: 2958853
[No Abstract] [Full Text] [Related]
3. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
Walker KJ; Turkes AO; Turkes A; Zwink R; Beacock C; Buck AC; Peeling WB; Griffiths K
J Endocrinol; 1984 Nov; 103(2):R1-4. PubMed ID: 6238116
[TBL] [Abstract][Full Text] [Related]
4. Zoladex treatment of symptomatic prostatic carcinoma.
Holdaway IM; Ibbertson HK; Croxson MS; Harvey V; Boulton J; Knox BS
Am J Clin Oncol; 1988; 11 Suppl 2():S123-6. PubMed ID: 2977267
[TBL] [Abstract][Full Text] [Related]
5. Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H).
Geldof AA; de Voogt HJ; Rao BR
Prostate; 1987; 11(3):281-90. PubMed ID: 2960958
[TBL] [Abstract][Full Text] [Related]
6. Treatment of advanced prostatic cancer with LHRH-analogues. Prevention of "flare-up" phenomenon.
Bouffioux C; Denis L; Mahler C; de Leval J
Prog Clin Biol Res; 1987; 243A():255-60. PubMed ID: 2958857
[No Abstract] [Full Text] [Related]
7. Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.
Kreis W; Ahmann FR; Jordan VC; de Haan H; Scott M
Br J Urol; 1988 Oct; 62(4):352-4. PubMed ID: 2973364
[TBL] [Abstract][Full Text] [Related]
8. Goserelin--another LH-RH analog for prostate cancer.
Med Lett Drugs Ther; 1990 Nov; 32(830):102. PubMed ID: 1700261
[No Abstract] [Full Text] [Related]
9. Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
Ahmed SR; Shalet SM; Grant J; Howell A; Blacklock NJ
Br Med J (Clin Res Ed); 1984 Sep; 289(6448):831. PubMed ID: 6236870
[No Abstract] [Full Text] [Related]
10. Response to orchiectomy following Zoladex therapy for metastatic prostate carcinoma.
Silver RI; Straus FH; Vogelzang NJ; Kellman H; Chodak GW
Urology; 1991 Jan; 37(1):17-21. PubMed ID: 1702566
[TBL] [Abstract][Full Text] [Related]
11. LHRH-analogues therapy for metastatic prostate cancer.
Debruyne FM; Fernandez del Moral P; Geboers AD
Prog Clin Biol Res; 1988; 260():27-39. PubMed ID: 2966406
[No Abstract] [Full Text] [Related]
12. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
[TBL] [Abstract][Full Text] [Related]
13. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
[TBL] [Abstract][Full Text] [Related]
14. Results obtained in the treatment of prostate cancer patients with Zoladex.
Williams G; Kerle DJ; Roe SM; Yeo T; Bloom SR
Prog Clin Biol Res; 1985; 185A():287-95. PubMed ID: 3162175
[No Abstract] [Full Text] [Related]
15. A new hormonal therapy for prostatic cancer: long-term clinical and hormonal response.
Ahmed SR; Grant JB; Shalet SM; Howell A; Costello CB; Weatherson T; Blacklock NJ
Br J Urol; 1986 Oct; 58(5):534-8. PubMed ID: 2946355
[TBL] [Abstract][Full Text] [Related]
16. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
Dijkman GA; Fernandez del Moral P; Plasman JW; Pull HC; van der Meijden AP; Debruyne FM; Hutchinson FG; Furr BJ
Eur Urol; 1990; 18 Suppl 3():22-5. PubMed ID: 2151271
[TBL] [Abstract][Full Text] [Related]
17. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
Debruyne FM; Denis L; Lunglmayer G; Mahler C; Newling DW; Richards B; Robinson MR; Smith PH; Weil EH; Whelan P
J Urol; 1988 Oct; 140(4):775-7. PubMed ID: 2971119
[TBL] [Abstract][Full Text] [Related]
18. Can combined DES and LHRH depot therapy (ICI 118630) prevent endocrinologic and clinical flare-up in metastatic prostate cancer?
Fernandez del Moral P; Litjens TT; Weil EH; Debruyne FM
Urology; 1988 Aug; 32(2):137-40. PubMed ID: 2969641
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma.
Eisenberger MA; O'Dwyer PJ; Friedman MA
J Clin Oncol; 1986 Mar; 4(3):414-24. PubMed ID: 2936872
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of treating advanced prostatic cancer with the LH-RH analogue Zoladex.
Beacock CJ
Am J Clin Oncol; 1988; 11 Suppl 2():S115-6. PubMed ID: 2977264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
